Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1989 1
1990 3
1991 4
1992 2
1994 2
1995 2
1996 3
1997 8
1998 1
1999 3
2000 2
2001 2
2003 2
2004 3
2005 3
2006 6
2007 2
2008 1
2009 1
2010 2
2011 2
2015 2
2016 3
2017 1
2018 2
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

60 results
Results by year
Filters applied: . Clear all
Page 1
Cell volume regulation in the nephron.
Montrose-Rafizadeh C, Guggino WB. Montrose-Rafizadeh C, et al. Annu Rev Physiol. 1990;52:761-72. doi: 10.1146/ Annu Rev Physiol. 1990. PMID: 2158770 Review.
Structural basis for GPR40 allosteric agonism and incretin stimulation.
Ho JD, Chau B, Rodgers L, Lu F, Wilbur KL, Otto KA, Chen Y, Song M, Riley JP, Yang HC, Reynolds NA, Kahl SD, Lewis AP, Groshong C, Madsen RE, Conners K, Lineswala JP, Gheyi T, Saflor MD, Lee MR, Benach J, Baker KA, Montrose-Rafizadeh C, Genin MJ, Miller AR, Hamdouchi C. Ho JD, et al. Among authors: montrose rafizadeh c. Nat Commun. 2018 Apr 25;9(1):1645. doi: 10.1038/s41467-017-01240-w. Nat Commun. 2018. PMID: 29695780 Free PMC article.
A Novel Aldosterone Antagonist Limits Renal Injury in 5/6 Nephrectomy.
Fujihara CK, Kowala MC, Breyer MD, Sena CR, Rodrigues MV, Arias SCA, Fanelli C, Malheiros DM, Jadhav PK, Montrose-Rafizadeh C, Krieger JE, Zatz R. Fujihara CK, et al. Among authors: montrose rafizadeh c. Sci Rep. 2017 Aug 11;7(1):7899. doi: 10.1038/s41598-017-08383-2. Sci Rep. 2017. PMID: 28801620 Free PMC article.
Discovery of 6-(4-{[5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl]methoxy}piperidin-1-yl)-1-methyl-1H-indole-3-carboxylic Acid: A Novel FXR Agonist for the Treatment of Dyslipidemia.
Genin MJ, Bueno AB, Agejas Francisco J, Manninen PR, Bocchinfuso WP, Montrose-Rafizadeh C, Cannady EA, Jones TM, Stille JR, Raddad E, Reidy C, Cox A, Michael MD, Michael LF. Genin MJ, et al. Among authors: montrose rafizadeh c. J Med Chem. 2015 Dec 24;58(24):9768-72. doi: 10.1021/acs.jmedchem.5b01161. Epub 2015 Dec 2. J Med Chem. 2015. PMID: 26568144 Clinical Trial.
Discovery of LY3104607: A Potent and Selective G Protein-Coupled Receptor 40 (GPR40) Agonist with Optimized Pharmacokinetic Properties to Support Once Daily Oral Treatment in Patients with Type 2 Diabetes Mellitus.
Hamdouchi C, Maiti P, Warshawsky AM, DeBaillie AC, Otto KA, Wilbur KL, Kahl SD, Patel Lewis A, Cardona GR, Zink RW, Chen K, Cr S, Lineswala JP, Neathery GL, Bouaichi C, Diseroad BA, Campbell AN, Sweetana SA, Adams LA, Cabrera O, Ma X, Yumibe NP, Montrose-Rafizadeh C, Chen Y, Miller AR. Hamdouchi C, et al. Among authors: montrose rafizadeh c. J Med Chem. 2018 Feb 8;61(3):934-945. doi: 10.1021/acs.jmedchem.7b01411. Epub 2018 Jan 5. J Med Chem. 2018. PMID: 29236497
Novel 3-aryl indoles as progesterone receptor antagonists for uterine fibroids.
Richardson TI, Clarke CA, Yu KL, Yee YK, Bleisch TJ, Lopez JE, Jones SA, Hughes NE, Muehl BS, Lugar CW, Moore TL, Shetler PK, Zink RW, Osborne JJ, Montrose-Rafizadeh C, Patel N, Geiser AG, Galvin RJ, Dodge JA. Richardson TI, et al. Among authors: montrose rafizadeh c. ACS Med Chem Lett. 2010 Dec 9;2(2):148-53. doi: 10.1021/ml100220b. eCollection 2011 Feb 10. ACS Med Chem Lett. 2010. PMID: 24900294 Free PMC article.
Identification of potent and selective retinoic acid receptor gamma (RARγ) antagonists for the treatment of osteoarthritis pain using structure based drug design.
Hughes NE, Bleisch TJ, Jones SA, Richardson TI, Doti RA, Wang Y, Stout SL, Durst GL, Chambers MG, Oskins JL, Lin C, Adams LA, Page TJ, Barr RJ, Zink RW, Osborne H, Montrose-Rafizadeh C, Norman BH. Hughes NE, et al. Among authors: montrose rafizadeh c. Bioorg Med Chem Lett. 2016 Jul 15;26(14):3274-3277. doi: 10.1016/j.bmcl.2016.05.056. Epub 2016 May 20. Bioorg Med Chem Lett. 2016. PMID: 27261179
Design and synthesis of a novel class of dual PPARgamma/delta agonists.
Gonzalez IC, Lamar J, Iradier F, Xu Y, Winneroski LL, York J, Yumibe N, Zink R, Montrose-Rafizadeh C, Etgen GJ, Broderick CL, Oldham BA, Mantlo N. Gonzalez IC, et al. Among authors: montrose rafizadeh c. Bioorg Med Chem Lett. 2007 Feb 15;17(4):1052-5. doi: 10.1016/j.bmcl.2006.11.029. Epub 2006 Nov 15. Bioorg Med Chem Lett. 2007. PMID: 17129725
The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470).
Hamdouchi C, Kahl SD, Patel Lewis A, Cardona GR, Zink RW, Chen K, Eessalu TE, Ficorilli JV, Marcelo MC, Otto KA, Wilbur KL, Lineswala JP, Piper JL, Coffey DS, Sweetana SA, Haas JV, Brooks DA, Pratt EJ, Belin RM, Deeg MA, Ma X, Cannady EA, Johnson JT, Yumibe NP, Chen Q, Maiti P, Montrose-Rafizadeh C, Chen Y, Reifel Miller A. Hamdouchi C, et al. Among authors: montrose rafizadeh c. J Med Chem. 2016 Dec 22;59(24):10891-10916. doi: 10.1021/acs.jmedchem.6b00892. Epub 2016 Nov 11. J Med Chem. 2016. PMID: 27749056
60 results